Table 1 TAMs related anticancer drugs and candidate anticancer drugs
From: Targeting tumor-associated macrophages for cancer treatment
Targeting TAMs strategies | Name | Target | Inhibitor type | Cancer type | Refs. | Â |
|---|---|---|---|---|---|---|
Phagocytosis | RRX-001 | CD47, SIRP-α | SMC | Non small-cell lung cancer | [83] |  |
| Â | Hu5F9-G4 | CD47 | mAb | Advanced tumors | [52] | Â |
Depletion of M2-like TAMs | Zoledronate | NA | SMC | Mammary carcinoma | Â | |
TAMs recruitment | Pexidatintinib | CSF-1R | SMC | Advanced solid tumors | [64] | Â |
| Â | D2923 | CSF-1R | SMC | Myelogenous leukemia | [66] | Â |
| Â | Emactuzumab | CSF-1R | mAb | Advanced solid tumors | [96] | Â |
|  | 3D185 | CSF-1R | SMC | Colorectal cancer | [76] |  |
| Â | PF-04136309 | CCR2 | SMC | Pancreatic cancer | [69] | Â |
| Â | CCX872 | CCR2 | SMC | Pancreatic cancer | [71] | Â |
| Â | CCR2i | CCR2 | SMC | Cutaneous t-cell lymphoma | [106] | Â |
| Â | mNOX-E36 | CCL2 | SMC | Glioblastoma | [70] | Â |
TAMs re-programming | R848 | TLR7/8 | SMC | Colorectal cancer | [80] |  |
| Â | lefitolimod | TLR9 | SMC | Small-cell lung cancer | [81] | Â |
|  | RP6530 | PI3Kδ/γ | SMC | Hodgkin lymphoma | [84] |  |
Suppressing the immunosuppressive TME | Anti-MARCO | MARCO | mAb | Breast and colon carcinoma | [91] | Â |
SMC small molecule compound, mAb monoclonal antibody | ||||||